Cardinal Health 414 Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CARDINAL HEALTH 414, and what generic alternatives to CARDINAL HEALTH 414 drugs are available?
CARDINAL HEALTH 414 has five approved drugs.
There are two US patents protecting CARDINAL HEALTH 414 drugs.
There are thirty patent family members on CARDINAL HEALTH 414 drugs in twelve countries and seventy-one supplementary protection certificates in nine countries.
Summary for Cardinal Health 414
| International Patents: | 30 |
| US Patents: | 2 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Cardinal Health 414
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardinal Health 414 | TECHNETIUM TC-99M MEDRONATE KIT | technetium tc-99m medronate kit | INJECTABLE;INJECTION | 018107-001 | Approved Prior to Jan 1, 1982 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | 9,439,985 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cardinal Health 414 | SODIUM FLUORIDE F-18 | sodium fluoride f-18 | INJECTABLE;INTRAVENOUS | 203780-001 | Jul 30, 2015 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cardinal Health 414 | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 203603-001 | Nov 13, 2015 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | 6,409,990 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cardinal Health 414 | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 203603-002 | Sep 27, 2018 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cardinal Health 414 Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6509796 | ⤷ Sign Up |
| Japan | 2021088566 | ⤷ Sign Up |
| Netherlands | 300736 | ⤷ Sign Up |
| South Korea | 20170027874 | ⤷ Sign Up |
| European Patent Office | 1178838 | ⤷ Sign Up |
| China | 102301429 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2010087959 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cardinal Health 414 Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1948158 | 1690020-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
| 1178838 | 15C0033 | France | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121 |
| 1912999 | 1490062-5 | Sweden | ⤷ Sign Up | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| 1874117 | SPC/GB14/041 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTERED: UK EU/1/13/892/001-006 20140121 |
| 2380576 | 2020/043 | Ireland | ⤷ Sign Up | PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; NAT REGISTRATION NO/DATE: PA2103/003/001 20170602; FIRST REGISTRATION NO/DATE: SE/H/1547/001/DC 20160729 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 2673237 | LUC00111 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
